Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02293265 · ClinicalTrials.gov registry record · Phase 3
Cross-sectional Study for Identification and Description of Severe Asthma Patients
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 767
- Enrollment target
NCT02293265 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 767 participants.
The verdict
NCT02293265, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 767 participants
- Enrollment target
Study Summary
This will be a non-drug interventional cross-sectional study, where the screening visit and study visit can occur on the same day. Investigational product will not be administered. Approximately 790 subjects with severe asthma will be screened to achieve a total of at least 750 evaluable study subjects. The study will not include a run-in or follow-up period. This study will provide a more reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab. This study aims to estimate the potential overlap of patients eligible for treatment with mepolizumab and those eligible for treatment with omalizumab and/or reslizumab. Additionally, the current study will also ascertain and describe reslizumab eligibility with respect to both mepolizumab and omalizumab, in the severe asthma patient population.
Interventions
- DRUG Short Acting Beta Agonist (SABA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 767 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02293265
The ClinicalTrials.gov registry entry for NCT02293265 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 767 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Short Acting Beta Agonist (SABA) is the first listed.
NCT02293265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02293265 about?
NCT02293265 is a clinical study titled "Cross-sectional Study for Identification and Description of Severe Asthma Patients". This will be a non-drug interventional cross-sectional study, where the screening visit and study visit can occur on the same day. Investigational product will not be administered. Approximately 790 subjects with severe asthma will be screened to achieve a total of at least 750 evaluable study subje...
What is the current status of trial NCT02293265?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 767 participants. The study started on 2014-12. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02293265?
The interventions under investigation include: Short Acting Beta Agonist (SABA) (DRUG).
Who is sponsoring clinical trial NCT02293265?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.